Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!
John A. Roberts, insider at Vyant Bio
John A. Roberts Insider Alerts

Get notified the next time John A. Roberts buys or sells Vyant Bio stock. Enter your email address below to get our daily insider buying and selling report.

John A. Roberts Insider Information

CEO of Vyant Bio
Mr. Jay Roberts has been the President and Chief Executive Officer of Vyant Bio, Inc. since 2018. Mr. Roberts had previously served as the Chief Operating Officer of Cancer Genetics. Prior to joining Cancer Genetics, Mr. Roberts served as the Chief Financial Officer for VirMedica, Inc., an innovative technology solutions company that provides an end-to-end platform that enables specialty-drug manufacturers and pharmacies to optimize product commercialization and management. Before VirMedica, Mr. Roberts was the Chief Financial and Administrative Officer for AdvantEdge Healthcare Solutions Inc., a global healthcare analytics and services organization. Prior to that, Mr. Roberts also served as the Chief Financial Officer and Treasurer for InfoLogix, Inc., a publicly-traded, healthcare-centric mobile software and solutions provider. He has also held CFO roles at leading public medical device and healthcare services firms including Clarient, Inc., a publicly-traded provider of diagnostic laboratory services, and Daou Systems, Inc., a publicly-traded healthcare IT software development and services firm. In addition, he has held key senior executive roles with MEDecision, Inc., HealthOnline, Inc., and the Center for Health Information. Mr. Roberts earned a Bachelor of Science and a master’s degree in Business Administration from the University of Maine. He is a member of the Fellows and a former member of the Board of Directors and Past Chair for the Drug Information Association, a global neutral forum enabling drug developers and regulators access to education and collaboration. Mr. Roberts also serves on the Board of Directors of Cohere-Med Inc., a clinical analytics company.

What is John A. Roberts' net worth?

The estimated net worth of John A. Roberts is at least $616,253.52 as of May 26th, 2021. Mr. Roberts owns 305,076 shares of Vyant Bio stock worth more than $616,254 as of November 29th. This net worth estimate does not reflect any other investments that Mr. Roberts may own. Learn More.

How do I contact John A. Roberts?

The corporate mailing address for Mr. Roberts and other Vyant Bio executives is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. Vyant Bio can also be reached via phone at (201) 479-1357 and via email at [email protected]

Has John A. Roberts been buying or selling shares of Vyant Bio?

Over the course of the past ninety days, John A. Roberts has bought $10,100.00 of Vyant Bio stock. Most recently, on Wednesday, November 24th, John A. Roberts bought 5,000 shares of Vyant Bio stock. The stock was acquired at an average cost of $2.02 per share, with a total value of $10,100.00.

Who are Vyant Bio's active insiders?

Vyant Bio's insider roster includes Marcus Boehm (Director), R. Fletcher (Director), Paul Hansen (Director), John Roberts (CEO), and Yung-Ping Yeh (Insider).

Are insiders buying or selling shares of Vyant Bio?

During the last twelve months, Vyant Bio insiders bought shares 15 times. They purchased a total of 110,687 shares worth more than $319,524.21. The most recent insider tranaction occured on November, 24th when CEO John A Roberts bought 5,000 shares worth more than $10,100.00. Insiders at Vyant Bio own 15.0 % of the company.

Information on this page was last updated on 11/24/2021.

John A. Roberts Insider Trading History at Vyant Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/24/2021Buy5,000$2.02$10,100.00View SEC Filing Icon  
8/23/2021Buy10,406$2.41$25,078.46View SEC Filing Icon  
5/26/2021Buy7,041$3.55$24,995.55305,076View SEC Filing Icon  
5/24/2021Buy7,440$3.38$25,147.20305,076View SEC Filing Icon  
1/31/2019Buy185,436$0.23$42,650.28297,636View SEC Filing Icon  
1/14/2019Buy100,000$0.23$23,000.00112,200View SEC Filing Icon  
12/15/2017Buy12,200$2.00$24,400.0012,200View SEC Filing Icon  
See Full Table

John A. Roberts Buying and Selling Activity at Vyant Bio

This chart shows John A Roberts's buying and selling at Vyant Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vyant Bio Company Overview

Vyant Bio logo
Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.
Read More

Today's Range

Now: $2.02
Low: $2.02
High: $2.02

50 Day Range

MA: $2.30
Low: $1.99
High: $2.96

2 Week Range

Now: $2.02
Low: $1.96
High: $17.50


50 shs

Average Volume

904,632 shs

Market Capitalization

$58.56 million

P/E Ratio


Dividend Yield



Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity